TrialThe New England journal of medicine2023

Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.

The primary results report of NCT02344290. Its numbers are set against the trial’s posted results below.

What the trial testedrandomised · 7,769 people · 2023

Randomised comparison

Doesn’t vote: the registry posted this outcome, and its result counts

−35%−52% to −10%

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.65, 95% CI 0.48–0.90

Same verdict as the posted result, different numberThis paper HR 0.65 (0.48–0.90)Posted, primary outcome HR 0.64 (0.48–0.84)Incidence Rate of Major Adverse Cardiovascular Event (MACE)Another analysis of the same outcome: a different population, model or data cut. The trial counts once.

the abstract, start to end

… in the placebo group (hazard ratio, 0.65; 95% confidence interval [CI], …

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

HR 0.650.48–0.90

StatinsCardiovascular events

1 / 3

2023

…

2024

2025

2026

this paperpooled ittrialcites it